...
首页> 外文期刊>Prescrire international >Drug research and development: public investors with an ambivalent role
【24h】

Drug research and development: public investors with an ambivalent role

机译:药物研发:公共投资者具有矛盾作用的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Public institutions invest in pharmaceutical companies. Their financial interests sometimes conflict with access to treatment by the very people whose money they are managing, as evidenced by the excessive prices for some drugs. Patients and company shareholders have divergent interests when the price of drugs is such that it becomes an obstacle to access. One study has now shown that a substantial proportion of shareholders in pharmaceutical companies are in fact public or quasi-public investors. According to this study, based mainly on data from the Organisation for Economic Cooperation and Development (OECD), around 50 of the 162 billion US dollars spent annually on research and development (R&D) by pharmaceutical firms worldwide comes from public or quasi-public investors, including pension funds (in countries where pensions are capitalised, and not based on redistribution), sovereign wealth funds (investment funds held by a State), and banks with partial or total public ownership (1 ). These investors, tasked with representing the public, are de facto major players in the financing of pharmaceutical R&D.
机译:公共机构投资制药公司。他们的经济利益有时与他们管理的人获得治疗的机会相冲突,一些药物的价格过高就是明证。当药品的价格成为获取药品的障碍时,患者和公司股东有着不同的利益。一项研究表明,制药公司的大部分股东实际上是公共或准公共投资者。根据这项研究,主要基于经济合作与发展组织(OECD)的数据,全球制药公司每年用于研发(R&D)的1620亿美元中,约有50美元来自公共或准公共投资者,包括养老基金(在养老金资本化的国家,而不是基于再分配),主权财富基金(国家持有的投资基金)和部分或全部公有制的银行(1)。这些负责代表公众的投资者实际上是药品研发融资的主要参与者。

著录项

  • 来源
    《Prescrire international》 |2021年第222期|共1页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号